Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Blood Test for Alzheimer's Amyloid Assessment

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at chosun.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Roche's Elecsys pTau217 blood test has received FDA approval to assess amyloid-beta accumulation in the brain, aiding early Alzheimer's diagnosis using simple blood draws instead of expensive PET scans or invasive procedures.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 24 Aug 2026 and 26 Aug 2026.

◆ ◆ The Wire takeaway

You now have a faster, cheaper gateway into Alzheimer’s diagnostics without brain scans or spinal taps. Labs and Medtech firms can expand testing quickly on existing devices to tap this newly accessible market.

◆ Coverage

3 sources · first reported 24 Aug 2026 · latest 26 Aug 2026

◆ Related on Wire

◆ Topics

Medtechalzheimersblood-testFDA-approvaldiagnosticsmedtechroche